N/A
N=8,493
Monitoring and Management for Metabolic Side Effects of Antipsychotics
Mental Health · Psychotic Disorders
Bottom Line
View on ClinicalTrials.gov: NCT01875861 ↗Enrolled (actual)
8,493
Serious AEs
0.0%
Results posted
Feb 2019
Primary outcome: Primary: Change in Site-level Rates of Weight Monitoring at Baseline (Within 30 Days of a New Antipsychotic Prescription) — 1811; 1410; 1598; 1109 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Evidence-Based Quality Improvement Plus Facilitation (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- VA Office of Research and Development
- Primary completion
- Mar 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Site-level Rates of Weight Monitoring at Baseline (Within 30 Days of a New Antipsychotic Prescription) |
1811; 1410; 1598; 1109; 1384; 1043 | — |
| SECONDARY Change in Site-level Rates of Weight Monitoring at Follow-up (From 31-120 Days After a New Antipsychotic Prescription) |
1696; 1337; 1477; 1005; 1265; 992 | — |
| SECONDARY Change in Site-level Rates of Management for Obesity or Weight Gain Within 30 Days After a Recording of 5% Gain in Body Weight |
25; 23; 46; 28; 50; 65 | — |
Summary
The purpose of this study is to test an approach for implementing guideline recommendations for assessing and managing metabolic side effects (including weight gain, diabetes, elevated lipids) in patients prescribed antipsychotic medications.
Eligibility Criteria
Inclusion Criteria
- Providers involved in antipsychotic management or management of metabolic side effects and related conditions
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT01875861). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.